Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
This study is ongoing, but not recruiting participants.
Study NCT01296763   Information provided by Sidney Kimmel Comprehensive Cancer Center

First Received on January 21, 2011.   Last Updated on May 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pancreatic Cancer
Additional conditions recognized in this trial
Pancreatic Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Interventions listed in this trial
ICM plus Olaparib
ICM without Olaparib
Additional drug interventions recognized in this trial
Carboplatin
Cisplatin
Irinotecan
Mitomycin
Mitomycins
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services